- Home
- PRTC vs ITOS Comparison
PRTC vs ITOS Comparison
Compare PRTC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- ITOS
- Stock Information
- Founded
- PRTC 2015
- ITOS 2011
- Country
- PRTC United States
- ITOS United States
- Employees
- PRTC N/A
- ITOS N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRTC Health Care
- ITOS Health Care
- Exchange
- PRTC Nasdaq
- ITOS Nasdaq
- Market Cap
- PRTC 439.8M
- ITOS 381.2M
- IPO Year
- PRTC N/A
- ITOS 2020
- Fundamental
- Price
- PRTC N/A
- ITOS $10.18
- Analyst Decision
- PRTC Buy
- ITOS Hold
- Analyst Count
- PRTC 1
- ITOS 6
- Target Price
- PRTC $45.00
- ITOS $10.60
- AVG Volume (30 Days)
- PRTC 5.9K
- ITOS 911.5K
- Earning Date
- PRTC 08-27-2025
- ITOS 08-07-2025
- Dividend Yield
- PRTC N/A
- ITOS N/A
- EPS Growth
- PRTC N/A
- ITOS N/A
- EPS
- PRTC 0.21
- ITOS N/A
- Revenue
- PRTC $4,828,000.00
- ITOS $35,000,000.00
- Revenue This Year
- PRTC $35.98
- ITOS N/A
- Revenue Next Year
- PRTC $115.38
- ITOS N/A
- P/E Ratio
- PRTC $7.93
- ITOS N/A
- Revenue Growth
- PRTC 44.98
- ITOS 177.89
- 52 Week Low
- PRTC $13.30
- ITOS $4.80
- 52 Week High
- PRTC $25.00
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- PRTC 43.39
- ITOS 67.13
- Support Level
- PRTC $16.50
- ITOS $9.95
- Resistance Level
- PRTC $18.40
- ITOS $10.19
- Average True Range (ATR)
- PRTC 0.45
- ITOS 0.15
- MACD
- PRTC -0.17
- ITOS -0.09
- Stochastic Oscillator
- PRTC 20.88
- ITOS 84.75
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.